ValuEngine downgraded shares of Inogen (NASDAQ:INGN) from a buy rating to a hold rating in a research report sent to investors on Wednesday.
A number of other equities analysts have also commented on the stock. Needham & Company LLC restated a buy rating and issued a $280.00 price target (down from $296.00) on shares of Inogen in a research report on Wednesday. BidaskClub lowered shares of Inogen from a hold rating to a sell rating in a research report on Saturday, October 27th. Zacks Investment Research upgraded shares of Inogen from a hold rating to a buy rating and set a $290.00 price target on the stock in a research report on Thursday, September 27th. Finally, Piper Jaffray Companies boosted their price target on shares of Inogen from $245.00 to $290.00 and gave the company an overweight rating in a research report on Wednesday, September 12th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $244.67.
Shares of Inogen stock opened at $148.51 on Wednesday. Inogen has a twelve month low of $111.49 and a twelve month high of $287.79. The stock has a market cap of $3.18 billion, a PE ratio of 113.37, a price-to-earnings-growth ratio of 2.89 and a beta of 1.56.
In other Inogen news, Director Raymond Huggenberger sold 10,500 shares of the business’s stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $282.57, for a total value of $2,966,985.00. Following the transaction, the director now directly owns 8,797 shares in the company, valued at $2,485,768.29. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Heath Lukatch sold 500 shares of the business’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $193.97, for a total transaction of $96,985.00. Following the completion of the transaction, the director now owns 1,489 shares in the company, valued at $288,821.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,000 shares of company stock worth $11,098,610. Company insiders own 5.29% of the company’s stock.
Several hedge funds have recently made changes to their positions in the company. CIBC World Markets Inc. lifted its position in shares of Inogen by 71.0% during the third quarter. CIBC World Markets Inc. now owns 14,593 shares of the medical technology company’s stock worth $3,562,000 after purchasing an additional 6,057 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Inogen by 1.2% during the third quarter. Bank of New York Mellon Corp now owns 207,765 shares of the medical technology company’s stock worth $50,720,000 after purchasing an additional 2,422 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of Inogen by 85.2% during the third quarter. Janus Henderson Group PLC now owns 7,810 shares of the medical technology company’s stock worth $1,907,000 after purchasing an additional 3,593 shares in the last quarter. AXA acquired a new position in shares of Inogen during the third quarter worth approximately $1,587,000. Finally, Alliancebernstein L.P. lifted its position in shares of Inogen by 43.3% during the third quarter. Alliancebernstein L.P. now owns 373,794 shares of the medical technology company’s stock worth $91,251,000 after purchasing an additional 113,024 shares in the last quarter. Institutional investors own 96.67% of the company’s stock.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: What is the yield curve?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.